Dr. Ellis Discusses the Cell-Proliferation Marker Ki67

Matthew J. Ellis, MD, PhD
Published: Wednesday, Aug 24, 2011

Matthew J. Ellis, MD, PhD, director, Section of Breast Oncology, Division of Oncology, Department of Medicine, Washington University, St Louis, MO, discusses the cell-proliferation marker Ki67.

Ellis explains that the marker has been examined for many years because of its ability to show how many tumor cells are actively committed to cell division. An overexpression of Ki67 generally translates into a more aggressive clinical course. Despite this evidence there currently are not any guidelines or evidence to support testing for the marker in every tumor.
Matthew J. Ellis, MD, PhD, director, Section of Breast Oncology, Division of Oncology, Department of Medicine, Washington University, St Louis, MO, discusses the cell-proliferation marker Ki67.

Ellis explains that the marker has been examined for many years because of its ability to show how many tumor cells are actively committed to cell division. An overexpression of Ki67 generally translates into a more aggressive clinical course. Despite this evidence there currently are not any guidelines or evidence to support testing for the marker in every tumor.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x